Report top-line results for TRYBeCA-1 final analysis
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 27 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- 25 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Trial to continue as planned with final analysis expected to report in Q4 2021”
What we found
Evidence strength A What the grades mean
The company reported the top-line final results for the TRYbeCA-1 trial on October 25, 2021, which falls within the fourth quarter of 2021.
-
A Erytech Pharma S.A. 20-F filed 2022-04-27
“We reported top-line final results on October 25, 2021.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- TRYBeCA-1 final top-line results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Erytech Pharma S.A.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C624422-022516 · Corrections policy